RenehaVis™
Dual Molecular Weight Hyaluronic Acid, Dual Chamber Integrated Design Intra-Articular Injection
Detail INfo
- Manufacuter located in Switzerland🇨🇭
- The performance of RenehaVis™ is due to its biocompatibility and physicochemical properties. The LMW and HMW sodium hyaluronate contained in RenehaVis™ is a biopolymer composed of repeating disaccharide units of N-acetylglucosamine and glucuronic acid and though it is biosynthesised by the bacterium Streptococcus equi it has been shown to be the same as the sodium hyaluronate which is found in the human body
- The product is designed for the relief of pain and stiffness of the knee joint in patients with degenerative changes to the synovial joint
- The dosage regimen is injection into the affected synovial joint space once a week for up to three injections depending on the severity of the degenerative change to the knee joint
- The duration of effect in patients with grade 1 to 3 medial compartment osteoarthritis has been demonstrated to be up to twelve months
- Injection of RenehaVis™ should only be made by a Healthcare Professional trained in the technique. Please read the instructions carefully before use (Medical device License Number 031890, approved by TFDA)
FAQ
Does hyaluronic acids with different molecular weights have different properties?
How long do the effects of hyaluronic acid injections for treating degenerative arthritis last? Besides, does a higher single injection dose lead to better results?
Is it safe to use hyaluronic acid injection for intra-articular injections?
Can hyaluronic acid injections for knee OA be used for other joints? Moreover, if discomfort occurs after use, what should be done?
DOWNLOAD
File name
last updated
Download
RELATED
- Healthcare providers:please refer to this website (https://www.renehavis.com/-Healthcare-Professional-) for further details
- Patients and the public: please refer to this website (https://www.renehavis.com/-Patients-) for further details